Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

BACKGROUND: Treatments for Hepatitis C virus (HCV) infection have vastly improved over the past few decades with current regimens now offering pangenotypic activity with excellent cure rates reported in clinical trials, including in the HIV-HCV coinfected population. However, there is some concern t...

Descripción completa

Detalles Bibliográficos
Autores principales: Maughan, A., Sadigh, K., Angulo-Diaz, V., Mandimika, C., Villanueva, M., Lim, J. K., Ogbuagu, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500032/
https://www.ncbi.nlm.nih.gov/pubmed/31053098
http://dx.doi.org/10.1186/s12879-019-3974-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500032/
https://www.ncbi.nlm.nih.gov/pubmed/31053098
http://dx.doi.org/10.1186/s12879-019-3974-7

Ejemplares similares